Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMSCT with T-Cell Infusions for CML Failing Imatinib
NCT00416884Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2003
- Primary completion
- Mar 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in Chronic Myeloid Leukemia (CML), sponsored by OHSU Knight Cancer Institute. Started May 2003; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00416884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416884.